Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis

• Published in: Frontiers in endocrinology (Lausanne) Vol. 13; p. 846903
• Main Authors: Cignarelli, Angelo, Genchi, Valentina Annamaria, Le Grazie, Giulia, Caruso, Irene, Marrano, Nicola, Biondi, Giuseppina, D’Oria, Rossella, Sorice, Gian Pio, Natalicchio, Annalisa, Perrini, Sebastio, Laviola, Luigi, Giorgino, Francesco
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 21.02.2022
• Subjects: diabetes; Diabetes Mellitus, Type 2 - drug therapy; Endocrinology; GLP-1RAs; Glucagon-Like Peptide-1 Receptor - agonists; Growth Hormone; Human Growth Hormone - therapeutic use; Humans; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; insulin-like growth factor; Insulin-Like Growth Factor I; SGLT-2is; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; SGLT-2is; insulin-like growth factor; growth hormone; diabetes; GLP-1RAs
• ISSN: 1664-2392; 1664-2392
• DOI: 10.3389/fendo.2022.846903

Accumulating evidence supports the early use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose transporter-2 inhibitors (SGLT-2is) for the treatment of type 2 diabetes. Indeed, these compounds exert numerous pleiotropic actions that favorably affect metabolism and diabetes comorbidities, showing an additional effect beyond glucose control. Although a substantial amount of knowledge has been generated regarding the mechanism of action of both drug classes, much remains to be understood. Growth hormone (GH) is an important driver for multiple endocrine responses involving changes in glucose and lipid metabolism, and affects several tissues and organs (e.g., bone, heart). It acts directly on several target tissues, including skeletal muscle and bone, but several effects are mediated indirectly by circulating (liver-derived) or locally produced IGF-1. In consideration of the multiple metabolic and cardiovascular effects seen in subjects treated with GLP-1RAs and SGLT-2is (e.g., reduction of hyperglycemia, weight loss, free/fat mass and bone remodeling, anti-atherosclerosis, natriuresis), it is reasonable to speculate that GH and IGF-1 may play a about a relevant role in this context. This narrative mini-review aims to describe the involvement of the GH/IGF-1/IGF-1R axis in either mediating or responding to the effects of each of the two drug classes.